- Getting the Facts on Lymphoma vaccines - Lymphoma Research Foundation
- Familial (inherited) leukemia, lymphoma, and myeloma: an overview.
- FDA Approves VELCADE(R) (Bortezomib) for Injection for Aggressive Form of Non-Hodgkin
- Results Reported at the American Society of Hematology Annual Meeting Affirm Impressi
- FDA Okays Zolinza for Cutaneous T-cell Lymphoma Skin Lesions
- Possible Development of PML from Rituxan Treatment
- Phase III Trial of Galiximab for Follicular Non-Hodgkin's Lymphoma In Combination wit
- UCLA Researchers Discover Genes Linked to Lymphoma, Opening Way for New Targeted Drug
- Lombardi expert helps set new guidelines for assessing lymphoma treatment
- Seattle Genetics Granted Orphan Drug Designation for AML and Hodgkin’s Disease Drug
- Researchers Funded by The Leukemia & Lymphoma Society Studying Agent to Target Gene L
- What You Need To Know About Non-Hodgkin's Lymphoma
- Risk of lymphoma increases with hepatitis C virus infection
- New Lymphoma treatment fights SYK causing cell death
- Jefferson scientists studying the effects of high-dose vitamin C on non-Hodgkin lymph
- Yale study offers insight into possible cause of lymphoma
- Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lym
- Medarex Reports Phase 1/2 Clinical Data of MDX-060 in Lymphoma at American Associatio
- Researchers Determine Risk Factors for Rare, Deadly form of Lymphoma
- Study makes exciting progress in elucidating the mechanisms of bortezomib in lymphoma
- Cell death assays for lymphatic neoplasms
- New lymphoma therapy may be more effective with fewer side effects
- Tumor Lysis Syndrome
- Penn Vet Researchers Show Lymphoma Drug Shrinks Dog Tumors, Could Lead to Human Treat
- Wnt Signaling Inhibitors
- Low grade B-Cell Non-Hodgkins Lymphoma
- Exercise is good medicine for lymphoma patients
- Rituxan (rituximab) Maintenance Therapy
- Tyrosine Kinase Inhibitor in Mantle Cell Lymphoma
- Breast Cancer After Hodgkin's Lymphoma
- Vivia Biotech and Ferrer to develop new drug for Non-Hodgkins Lymphoma
- Myc-Driven Cancer Susceptible To Afinitor (everolimus)
- Treatment-Related AML in Non-Hodgkin's Lymphoma
- Will Adcetris increase cure rate of advanced Hodgkin lymphoma?